Table 3. The univariate and multivariable analyses of the HIV in-utero model using data from 3,707 HIV-1-infected mothers enrolled in the PHPT-1, PHPT-2, and PHPT-5 studies.
| Predictors | Logit coefficient(95%CI) | Odds ratio(95%CI) | RSE (%) a | BIC b |
|---|---|---|---|---|
| Univariate analysis | ||||
| Baseline model | -3.71 (-3.89, -3.53) | - | 2 | 791.42 |
| ZDV duration (weeks) | -0.09 (-0.15, -0.04) | 0.91 (0.86, 0.96) | 29 | 772.04 |
| VL before treatment initiation (log10 copies/mL) | 0.23 (0.158, 0.31) | 1.26 (1.17, 1.36) | 17 | 778.06 |
| CD4 (per 100 cell count) | -0.13 (-0.22, -0.04) | 0.88 (0.80, 0.96) | 34 | 784.04 |
| Gestational age at baseline (days) | 0.003 (0.001, 0.005) | 1.003 (1.001, 1.005) | 33 | 794.26 |
| Multivariable analysis | ||||
| Model 1 | 740.13 | |||
| VL | 0.43 (0.29, 0.58) | 1.54 (1.34, 1.78) | 17 | |
| ZDV duration | -0.21 (-0.27, -0.15) | 0.81 (0.77, 0.86) | 15 | |
| CD4 | -0.19 (-0.30, -0.08) | 0.83 (0.74, 0.92) | 30 | |
| Model 2 | 746.69 | |||
| VL before treatment | 0.44 (0.22, 0.66) | 1.55 (1.25, 1.93) | 26 | |
| ZDV duration | -0.22 (-0.28, -0.16) | 0.80 (0.76, 0.85) | 13 | |
| GA at baseline | 3.44e-007 (-0.004, 0.004) | 1.00 (0.99, 1.004) | 6.25e+005 | |
| Final model c | 735.96 | |||
| VL before treatment | 0.41 (0.30, 0.52) | 1.50 (1.34, 1.68) | 14 | |
| Duration of ZDV | -0.23 (-0.28,-0.17) | 0.80 (0.75, 0.84) | 13 |
a RSE%, relative standard error (standard error of estimate / estimate*100)
b Bayesian Information Criterion
c Random effect of individuals: η~N(0,0.5272)